Iovance Biotherapeutics, Inc. IOVA Foreign currency remeasurement (loss) gain on debt
Foreign currency remeasurement (loss) gain on debt at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt?
- Iovance Biotherapeutics, Inc. (IOVA) reported foreign currency remeasurement (loss) gain on debt of -$434K in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt changed year-over-year?
- Iovance Biotherapeutics, Inc.'s foreign currency remeasurement (loss) gain on debt decreased by 635.6% year-over-year, from -$59K to -$434K.
- What does foreign currency remeasurement (loss) gain on debt mean?
- Represents the net gain or loss resulting from the remeasurement of foreign currency-denominated debt or financial obligations. This metric reflects the impact of exchange rate fluctuations on the company's liabilities before accounting for tax effects. It is a critical indicator of exposure to international currency volatility.